Gufic Biosciences Limited (GUFICBIO.BO)
INR 317.25
(2.11%)
INR 317.25
(2.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.19 Billion INR | 4.53% |
| 2022 | 3.05 Billion INR | 479.0% |
| 2021 | 527.79 Million INR | -4.62% |
| 2020 | 553.35 Million INR | -54.68% |
| 2019 | 1.22 Billion INR | 29.74% |
| 2018 | 941.24 Million INR | 23.92% |
| 2017 | 759.55 Million INR | 41.27% |
| 2016 | 537.66 Million INR | 40.5% |
| 2015 | 382.68 Million INR | 36.37% |
| 2014 | 280.61 Million INR | -11.59% |
| 2013 | 317.41 Million INR | -7.27% |
| 2012 | 342.28 Million INR | 72.38% |
| 2011 | 198.55 Million INR | 13.48% |
| 2010 | 174.97 Million INR | 6.48% |
| 2009 | 164.32 Million INR | 12.15% |
| 2008 | 146.51 Million INR | -2.35% |
| 2007 | 150.04 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 3.19 Billion INR | 4.53% |
| 2023 Q2 | 3.54 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 3.19 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 FY | 3.05 Billion INR | 479.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.55 Billion INR | 0.0% |
| 2022 Q4 | 3.05 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 527.79 Million INR | 0.0% |
| 2021 FY | 527.79 Million INR | -4.62% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 235.68 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.23 Billion INR | 0.0% |
| 2020 FY | 553.35 Million INR | -54.68% |
| 2020 Q4 | 553.35 Million INR | 0.0% |
| 2019 Q4 | 1.22 Billion INR | 0.0% |
| 2019 Q2 | 1.09 Billion INR | 0.0% |
| 2019 FY | 1.22 Billion INR | 29.74% |
| 2018 Q4 | 941.24 Million INR | 0.0% |
| 2018 Q2 | 894.69 Million INR | 0.0% |
| 2018 FY | 941.24 Million INR | 23.92% |
| 2017 Q4 | 759.55 Million INR | 0.0% |
| 2017 FY | 759.55 Million INR | 41.27% |
| 2017 Q2 | 739.63 Million INR | 0.0% |
| 2016 Q4 | 537.66 Million INR | 0.0% |
| 2016 FY | 537.66 Million INR | 40.5% |
| 2016 Q2 | 381.9 Million INR | 0.0% |
| 2015 Q2 | 296.2 Million INR | 0.0% |
| 2015 Q4 | 382.68 Million INR | 0.0% |
| 2015 FY | 382.68 Million INR | 36.37% |
| 2014 Q2 | 254.48 Million INR | 0.0% |
| 2014 FY | 280.61 Million INR | -11.59% |
| 2014 Q4 | 280.61 Million INR | 0.0% |
| 2013 Q4 | 317.41 Million INR | 0.0% |
| 2013 FY | 317.41 Million INR | -7.27% |
| 2013 Q2 | 312.38 Million INR | 0.0% |
| 2012 Q4 | 342.28 Million INR | 0.0% |
| 2012 FY | 342.28 Million INR | 72.38% |
| 2011 Q4 | 198.55 Million INR | 0.0% |
| 2011 FY | 198.55 Million INR | 13.48% |
| 2010 FY | 174.97 Million INR | 6.48% |
| 2009 FY | 164.32 Million INR | 12.15% |
| 2008 FY | 146.51 Million INR | -2.35% |
| 2007 FY | 150.04 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 17.372% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 13.51% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 212.371% |
| Granules India Limited | 9.28 Billion INR | 65.604% |
| Indoco Remedies Limited | 6.47 Billion INR | 50.677% |
| Achyut Healthcare Limited | -3.74 Million INR | 85372.744% |
| Ajanta Pharma Limited | -954.9 Million INR | 434.518% |
| Alkem Laboratories Limited | -1.6 Billion INR | 298.479% |
| Alpa Laboratories Limited | 35.36 Million INR | -8932.936% |
| Brooks Laboratories Limited | 49.48 Million INR | -6355.122% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 163.728% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 3.172% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 375.907% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 75.263% |
| Eris Lifesciences Limited | 13.8 Billion INR | 76.863% |
| FDC Limited | -57.75 Million INR | 5631.093% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 174.542% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 176.915% |
| Ipca Laboratories Limited | 11.41 Billion INR | 72.017% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 329.819% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -65.259% |
| Lasa Supergenerics Limited | 205.79 Million INR | -1452.154% |
| Laurus Labs Limited | 24.38 Billion INR | 86.9% |
| Lupin Limited | 17.19 Billion INR | 81.42% |
| Mankind Pharma Limited | -9.9 Billion INR | 132.24% |
| Medicamen Biotech Limited | 160.31 Million INR | -1892.513% |
| Medico Remedies Limited | 78.67 Million INR | -3960.039% |
| Megasoft Limited | 1.28 Billion INR | -148.478% |
| NATCO Pharma Limited | -5.81 Billion INR | 154.913% |
| Piramal Pharma Limited | 42.27 Billion INR | 92.444% |
| RPG Life Sciences Limited | -364.7 Million INR | 975.875% |
| Sigachi Industries Limited | 859.94 Million INR | -271.454% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 104.408% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -2103.342% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -6812.46% |
| Unichem Laboratories Limited | 931.91 Million INR | -242.769% |
| Wanbury Limited | 1.1 Billion INR | -188.85% |
| Windlas Biotech Limited | -273.04 Million INR | 1269.908% |
| ZIM Laboratories Limited | 983.6 Million INR | -224.756% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 18.346% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 439.171% |
| Divi's Laboratories Limited | -39.77 Billion INR | 108.032% |
| Hester Biosciences Limited | 2.29 Billion INR | -39.445% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 236.044% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 1383.931% |
| Bal Pharma Limited | 1.26 Billion INR | -152.803% |
| Strides Pharma Science Limited | 23.25 Billion INR | 86.265% |
| Venus Remedies Limited | -267.7 Million INR | 1293.245% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | -22.299% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 48.121% |
| Shilpa Medicare Limited | 9.06 Billion INR | 64.78% |
| Aarti Drugs Limited | 5.54 Billion INR | 42.428% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 390.05% |
| Suven Life Sciences Limited | -1.63 Billion INR | 295.647% |
| Ind-Swift Limited | 9.5 Billion INR | 66.406% |
| Valiant Laboratories Limited | -295.03 Million INR | 1182.702% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | -13.225% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 68.149% |
| Themis Medicare Limited | 764.96 Million INR | -317.579% |
| Hikal Limited | 7.96 Billion INR | 59.906% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 89.964% |
| Sequent Scientific Limited | 4.17 Billion INR | 23.556% |
| Novartis India Limited | -5.89 Billion INR | 154.223% |
| Wockhardt Limited | 18.27 Billion INR | 82.516% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 88.201% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 17417.126% |
| Neuland Laboratories Limited | -214.05 Million INR | 1592.267% |
| Morepen Laboratories Limited | -231.17 Million INR | 1481.78% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -2561.066% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -227.35% |